Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report

about

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer

P2860

Q26771116-B9434AE6-CE66-47AF-A724-85AF07AF8424

P2860

Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report

Item

http://www.wikidata.org/entity/Q36838905

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prolonged survival with erloti ...... oma of the lung: a case report

@en

type

Item

label

Prolonged survival with erloti ...... oma of the lung: a case report

@en

prefLabel

Prolonged survival with erloti ...... oma of the lung: a case report

@en

P1476

Prolonged survival with erloti ...... oma of the lung: a case report

@en

P2093

María Ángeles Sala González

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.

P304

1434-1437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1080/15384047.2015.1070993

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26186355

http://www.w3.org/2001/XMLSchema#string

P932

4846105

http://www.w3.org/2001/XMLSchema#string

Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report

about

P2860

P2860

Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932